The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Relapse after HSCT 2021 | Patient selection for CAR-T therapy
Sergio Giralt, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses patient selection for chimeric antigen receptor T-cell (CAR-T) therapy, highlighting key challenges. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
Disclosures
Sergio Giralt, MD, PhD, discloses links to Amgen, Janssen, Celgene, Quintiles, Pfizer, CSL Behring, Sanof, Adienne, Kite, JAZZ and Actinuum.
